Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

Vanda Pharmaceuticals (ANAB) announced publication of a peer‑reviewed NEJM Evidence article reporting the pivotal phase III study of imsidolimab for Generalized Pustular Psoriasis (GPP).

Rhea-AI Summary

Vanda Pharmaceuticals (ANAB) announced publication of a peer‑reviewed NEJM Evidence article reporting the pivotal phase III study of imsidolimab for Generalized Pustular Psoriasis (GPP).

The study findings are included in a Biologics License Application (BLA) for imsidolimab submitted to the U.S. FDA, with a target action date of December 12, 2026.

Positive

• NEJM Evidence publication of pivotal phase III study
• Pivotal data included in BLA for imsidolimab
• FDA target action date set for December 12, 2026

Negative

• Final regulatory approval is pending; FDA decision expected by December 12, 2026

Argus Apr 29 session

+3.07% close to close Open Argus

Details

News Market Reaction – VNDA

On Apr 29, the first trading day after this news, VNDA closed 3.07% above the previous close.

Data tracked by StockTitan Argus for the Apr 29 session.

Market Context

This announcement highlights peer-reviewed Phase III data for imsidolimab in generalized pustular ps...

Analysis

This announcement highlights peer-reviewed Phase III data for imsidolimab in generalized pustular psoriasis, now published in NEJM Evidence and already included in a BLA with a defined FDA action date. It builds on prior disclosures that referenced the BLA in regulatory filings. Investors may focus on how this publication supports the overall late-stage portfolio outlined in recent SEC documents, alongside Vanda’s $216.1 million in 2025 revenue and $263.8 million year-end cash and securities.

Key Figures

2025 Revenue: $216.1 million Year-end Cash & Securities: $263.8 million 2025 Net Loss: $220.5 million +5 more

2025 Revenue

$216.1 million

Total revenue for 2025 from Fanapt, HETLIOZ and PONVORY

Year-end Cash & Securities

$263.8 million

Cash and securities balance at 2025 year-end

2025 Net Loss

$220.5 million

Net loss for 2025 after non-cash tax valuation allowance

Shelf Capacity

$200,000,000

Maximum aggregate amount under S-3 shelf registration filed Feb 12, 2026

Shares Outstanding

60,135,062 shares

Common shares outstanding as of record date April 17, 2026

CEO Stock Option

61,200 shares at $7.05

Option grant expiring February 15, 2033

Director RSU Grant

$390,000

Initial RSU grant value to director Charles C. Duncan on April 22, 2026

Director Annual Cash Fee

$50,000

Annual cash fee for outside director, paid quarterly

Historical Context

5 past events · Latest: Apr 22

5 events

1. Apr 22

   Board appointment

   24h Move

   -2.0%

   Added experienced biotech-focused director, expanding board to seven members.

2. Apr 09

   Regulatory policy comment

   24h Move

   +0.6%

   Company urged FDA to withdraw proposal extending drug review timelines.

3. Apr 08

   Clinical trial start

   24h Move

   +0.6%

   Initiated Phase 2 Thetis study of NEREUS™ for GLP-1–induced vomiting.

4. Mar 19

   Regulatory policy critique

   24h Move

   -16.9%

   Criticized FDA draft guidance on New Approach Methodologies as inadequate.

5. Mar 03

   FDA hearing granted

   24h Move

   -4.0%

   FDA granted rare Part 12 hearing on HETLIOZ® sNDA for jet lag disorder.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

generalized pustular psoriasis, biologics license application, u.s. food and drug administration, fda, +1 more

5 terms

generalized pustular psoriasis medical

"Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in New Engl"

A rare, severe form of psoriasis that causes sudden, widespread patches of pus-filled bumps, intense redness and peeling skin, often with fever and other body-wide symptoms; it can require hospitalization and can be life-threatening. Investors should care because the condition drives demand for specialized therapies, influences clinical trial urgency and regulatory attention, and can affect market size and pricing potential for drugs targeting this high-need patient group—like a small but high-impact niche in healthcare.

biologics license application regulatory

"included in the Biologics License Application (BLA) for imsidolimab for the treatme"

A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.

u.s. food and drug administration regulatory

"submitted to the U.S. Food and Drug Administration (FDA) with a target action date"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

fda regulatory

"submitted to the U.S. Food and Drug Administration (FDA) with a target action date"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

phase iii medical

"The findings of this pivotal phase III study are included in the Biologics License"

A Phase III trial is the late-stage clinical study that tests whether a medical treatment works and is safe in a large group of patients, often comparing it to standard care. Think of it as a final dress rehearsal or full-scale road test before regulators decide on approval; positive or negative results strongly influence a drug maker’s chance to sell the treatment, future revenue, and investment risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in New England Journal of Medicine (NEJM) Evidence¹.

The findings of this pivotal phase III study are included in the Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), submitted to the U.S. Food and Drug Administration (FDA) with a target action date of December 12, 2026.

References

1. Smieszek, S. et al. Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis. NEJM Evidence 5, (2026). 

About Imsidolimab

Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling and is being developed for GPP, a rare orphan indication. Regulatory and patent exclusivity for imsidolimab is expected to extend into the late 2030s. Vanda holds an exclusive global license for the development and commercialization of imsidolimab from AnaptysBio (Nasdaq: ANAB).

About Vanda Pharmaceuticals

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this press release, including, but not limited to statements regarding the anticipated timing of the completion of the FDA's review of the imsidolimab BLA; Vanda's plans to seek FDA approval of imsidolimab for the treatment of GPP; and the potential to extend regulatory and patent exclusivity for imsidolimab into the late 2030s, are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, the FDA's ability to complete its review of, and reach a decision with respect to, the imsidolimab BLA by December 12, 2026; Vanda's ability to obtain FDA approval of imsidolimab for the treatment of GPP; and Vanda's ability to satisfy the conditions necessary to extend regulatory and patent exclusivity for imsidolimab into the late 2030s. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized, or even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-the-publication-of-efficacy-and-safety-of-imsidolimab-for-generalized-pustular-psoriasis-in-nejm-evidence-302756392.html

SOURCE Vanda Pharmaceuticals Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vanda (ANAB) announce about imsidolimab on April 28, 2026?

They announced the NEJM Evidence publication of a pivotal phase III study for imsidolimab in GPP. According to the company, the study data are included in a BLA submitted to the U.S. FDA with a December 12, 2026 target action date.

Does the NEJM Evidence paper mean imsidolimab is FDA approved for GPP (ANAB)?

No, publication does not equal approval; the BLA is under review by the FDA. According to the company, the BLA submission includes the pivotal phase III findings and a target action date of December 12, 2026 for a regulatory decision.

What is included in Vanda's (ANAB) BLA for imsidolimab?

The BLA includes data from the pivotal phase III study published in NEJM Evidence. According to the company, those study results form part of the application submitted to the U.S. FDA for GPP treatment consideration.

When will the FDA decide on Vanda's (ANAB) imsidolimab BLA?

The FDA target action date for the BLA is December 12, 2026. According to the company, that date reflects the agency's planned review timeline after the BLA submission for imsidolimab in GPP.

How does the NEJM Evidence publication affect investors in Vanda (ANAB)?

Publication increases transparency around pivotal phase III data but does not guarantee approval or commercial outcome. According to the company, the results are part of the BLA under FDA review with a December 12, 2026 target action date.